CompletedNot Applicable

Predictive Value of AMH in IVF; a Prospective RCT

Sweden308 participantsStarted 2013-03

Plain-language summary

The primary aim of this trial is to compare two groups of women undergoing IVF (IVF=in vitro fertilisation ) treatment, to investigate if assessment of AMH (AMH=Anti-Müllerian hormone ), in addition to assessment of maternal age, AFC (AFC=antral follicle count ) and BMI (BMI=body mass index ) gives a more optimal COH (COH=controlled ovarian stimulation than does assessment of only age, AFC and BMI, measured as number of patients obtaining 5-12 oocytes during COH.

Who can participate

Age range18 Years – 40 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Indication for IVF with standard method for the couple exists (i.e. more than one year of infertility and work-up has been performed suggesting IVF as the proper treatment and no known severe male factor exists).
✓. Age \>18 and \< 40 years.
✓. BMI \> 18 and \< 35.
✓. First IVF treatment for the woman.
✓. Willing to participate in randomization between intervention group and control group and to sign informed consent.

Exclusion criteria

✕. IVF with ICSI (ICSI=intracytoplasmic sperm injection ) planned.
✕. Oocyte donation planned.
✕. Treatment with PGD (PGD=preimplantation genetic diagnosis ) planned.
✕. Medical or psychological condition indicating ineligibility for the study.
✕. Patient with insufficient knowledge of Swedish language to understand patient information.
✕. Previous participation in this study.

What they're measuring

Number of patients obtaining 5-12 oocytes during COH

Timeframe: 2 years

Trial details

NCT IDNCT02013973

SponsorAnn Thurin Kjellberg

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-05

View on ClinicalTrials.gov More Infertility trials